An Illustrated Guide to Cancer Biology
Autor Tomas Koltai, Larry Fliegelen Limba Engleză Paperback – sep 2025
- Contains more than 400 figures simplifying the understanding of cancer biology
- Combines molecular features with clinical approaches to support practicing oncologists
- Provides a detailed description of new developments in cancer biology including hypoxia, ROS (Reactive Oxygen Species), PPAR (Peroxisome proliferator-activated receptors) and alternative drug treatments
Preț: 1331.87 lei
Preț vechi: 1729.71 lei
-23% Nou
Puncte Express: 1998
Preț estimativ în valută:
254.85€ • 265.57$ • 211.02£
254.85€ • 265.57$ • 211.02£
Carte nepublicată încă
Doresc să fiu notificat când acest titlu va fi disponibil:
Se trimite...
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9780443363108
ISBN-10: 0443363102
Pagini: 1100
Dimensiuni: 216 x 276 mm
Editura: ELSEVIER SCIENCE
ISBN-10: 0443363102
Pagini: 1100
Dimensiuni: 216 x 276 mm
Editura: ELSEVIER SCIENCE
Cuprins
1. Introduction
2. Basics of oncological molecular biology
PART I
3. Basics of oncological molecular biology
PART II: JUNK DNA AND CANCER: POSSIBLE ROLE OF TRANSPOSONS.
4. Basics of oncological molecular biology
Part 3: THE LABORATORY IN MOLECULAR ONCOLOGY. A SYNOPSIS OF THE MOST IMPORTANT TOOLS
5. Basics of oncological molecular biology
PART 4: SOME BASIC DEFINITIONS
6. The Hanahan and Weinberg hallmarks of cancer
7. Biology of metastasis
8. Mitotic errors, mutations and DNA repair
9. Growth factors, their receptors and proliferative pathways
10. Angiogenesis
11. Hypoxia in cancer
12. The Unique Metabolism of Cancer Cells - Part 1: Carbohydrates
13. The Unique Metabolism of Cancer Cells - Part 2:
14. The Unique Metabolism of Cancer Cells - Part 3:
15. The Unique Metabolism of Cancer Cells - Part 4: Iron metabolism in cancer
16. Molecular mechanisms of action of chemotherapeutic drugs
17. ROS and cancer
18. Targeted Cancer Treatments - Part I
19. Targeted Cancer Treatments - Part II: Antibody Drug Conjugates for cancer treatment: present and future
20. Cancer and the immune system - Part I
21. Cancer and the immune system - Part II
22. Cancer and the immune system - Part III: Some caveats about immunology and cancer. A historical and clinical perspective
23. The tumor microenvironment - Part I: Cancer environment and Groucho Marx’s principles
24. The tumor microenvironment - Part II: CELLS IN THE TUMOR MICROENVIRONMENT
25. The tumor microenvironment - Part III: Non-cellular components of the tumor microenvironment
26. The tumor microenvironment – Part IV: Adhesion molecules
27. The tumor microenvironment - Part V: Cytokines
28. The tumor microenvironment - Part VI: Chemokines in the TME
29. Tumor heterogeneity: A different way of looking at cancer
30. Resistance to treatment and multidrug resistance (MDR)
31. Pancreatic cancer: a paradigm of difficulties and drug resistance
32. Cancer cachexia
33. Tumor markers
34. The origins and pathogenesis of cancer
35. Extracellular vesicles: Exosomes and microvesicles in cancer. A message in a bottle.
36. Cancer stem cells
37. Repurposing drugs and nutraceuticals for cancer treatment - PART 1: General Concept
38. Repurposing drugs and nutraceuticals for cancer treatment - PART 2: Repurposable Drugs
39. Repurposing drugs and nutraceuticals for cancer treatment - PART 3 Repurposing Metformin
40. Repurposing drugs and nutraceuticals for cancer treatment - PART 4 Repurposable Nutraceuticals
41. The metabolic control center: a survival hub for normal and cancer cells
42. pH homeostasis and ion channels in cancer
43. Tumor growth and genetic evolution - Part I: Tumor growth and kinetics
44. Protein degradation in cancer - Part 1
45. Protein degradation in cancer - Part II : The unfold protein response (UPR)
46. Cell migration in cancer - Part I: mechanisms of migration and invasion
47. Cell migration in cancer - Part II: Targeting cancer cell migration and invasion
48. Cell migration in cancer - Part III: The “go or grow” hypothesis and some caveats
49. RNA in cancer - Part I: MicroRNAs MiRs or miRNAs
50. RNA in cancer - Part II: Long non-coding RNA (lncRNA)
51. RNA in cancer - Part III: RNA binding proteins (RBPs)
52. Epigenetics and cancer
53. Peroxisome, peroxisome proliferators and peroxisome proliferator-activated receptors in cancer
54. The renin-angiotensin system signaling pathways and cancer: two sides of the same coin
55. Hormone-dependent cancer
56. Chapter 34 Part 1: Cancer and inflammation
57. Chapter 34 part 2: Links between inflammation and cancer
58. Chapter 34 part 3: Caveats about anti-inflammatory drugs and cancer
59. Summary and final words
2. Basics of oncological molecular biology
PART I
3. Basics of oncological molecular biology
PART II: JUNK DNA AND CANCER: POSSIBLE ROLE OF TRANSPOSONS.
4. Basics of oncological molecular biology
Part 3: THE LABORATORY IN MOLECULAR ONCOLOGY. A SYNOPSIS OF THE MOST IMPORTANT TOOLS
5. Basics of oncological molecular biology
PART 4: SOME BASIC DEFINITIONS
6. The Hanahan and Weinberg hallmarks of cancer
7. Biology of metastasis
8. Mitotic errors, mutations and DNA repair
9. Growth factors, their receptors and proliferative pathways
10. Angiogenesis
11. Hypoxia in cancer
12. The Unique Metabolism of Cancer Cells - Part 1: Carbohydrates
13. The Unique Metabolism of Cancer Cells - Part 2:
14. The Unique Metabolism of Cancer Cells - Part 3:
15. The Unique Metabolism of Cancer Cells - Part 4: Iron metabolism in cancer
16. Molecular mechanisms of action of chemotherapeutic drugs
17. ROS and cancer
18. Targeted Cancer Treatments - Part I
19. Targeted Cancer Treatments - Part II: Antibody Drug Conjugates for cancer treatment: present and future
20. Cancer and the immune system - Part I
21. Cancer and the immune system - Part II
22. Cancer and the immune system - Part III: Some caveats about immunology and cancer. A historical and clinical perspective
23. The tumor microenvironment - Part I: Cancer environment and Groucho Marx’s principles
24. The tumor microenvironment - Part II: CELLS IN THE TUMOR MICROENVIRONMENT
25. The tumor microenvironment - Part III: Non-cellular components of the tumor microenvironment
26. The tumor microenvironment – Part IV: Adhesion molecules
27. The tumor microenvironment - Part V: Cytokines
28. The tumor microenvironment - Part VI: Chemokines in the TME
29. Tumor heterogeneity: A different way of looking at cancer
30. Resistance to treatment and multidrug resistance (MDR)
31. Pancreatic cancer: a paradigm of difficulties and drug resistance
32. Cancer cachexia
33. Tumor markers
34. The origins and pathogenesis of cancer
35. Extracellular vesicles: Exosomes and microvesicles in cancer. A message in a bottle.
36. Cancer stem cells
37. Repurposing drugs and nutraceuticals for cancer treatment - PART 1: General Concept
38. Repurposing drugs and nutraceuticals for cancer treatment - PART 2: Repurposable Drugs
39. Repurposing drugs and nutraceuticals for cancer treatment - PART 3 Repurposing Metformin
40. Repurposing drugs and nutraceuticals for cancer treatment - PART 4 Repurposable Nutraceuticals
41. The metabolic control center: a survival hub for normal and cancer cells
42. pH homeostasis and ion channels in cancer
43. Tumor growth and genetic evolution - Part I: Tumor growth and kinetics
44. Protein degradation in cancer - Part 1
45. Protein degradation in cancer - Part II : The unfold protein response (UPR)
46. Cell migration in cancer - Part I: mechanisms of migration and invasion
47. Cell migration in cancer - Part II: Targeting cancer cell migration and invasion
48. Cell migration in cancer - Part III: The “go or grow” hypothesis and some caveats
49. RNA in cancer - Part I: MicroRNAs MiRs or miRNAs
50. RNA in cancer - Part II: Long non-coding RNA (lncRNA)
51. RNA in cancer - Part III: RNA binding proteins (RBPs)
52. Epigenetics and cancer
53. Peroxisome, peroxisome proliferators and peroxisome proliferator-activated receptors in cancer
54. The renin-angiotensin system signaling pathways and cancer: two sides of the same coin
55. Hormone-dependent cancer
56. Chapter 34 Part 1: Cancer and inflammation
57. Chapter 34 part 2: Links between inflammation and cancer
58. Chapter 34 part 3: Caveats about anti-inflammatory drugs and cancer
59. Summary and final words